Cingulate Inc. (CING) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Kansas City, KS, 미국. 현재 CEO는 Shane J. Schaffer.
CING 을(를) 보유 IPO 날짜 2021-12-08, 13 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $29.15M.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
